Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. (CARM) generates news primarily as a clinical-stage biopharmaceutical company that has focused on engineered macrophage and monocyte immunotherapies and, more recently, on corporate restructuring and wind down activities. News coverage of CARM reflects both its scientific developments and its significant corporate and listing transitions.
On the scientific side, Carisma has issued press releases on preclinical and clinical milestones across oncology and fibrosis. These include data on CT-0525, an ex vivo CAR-monocyte therapy for HER2-overexpressing solid tumors, CT-1119 for mesothelin-positive tumors, and engineered macrophage programs for liver fibrosis. The company has also reported preclinical results from its anti-GPC3 in vivo CAR-M program for hepatocellular carcinoma, developed in collaboration with Moderna, highlighting tumor-targeting activity and off-the-shelf potential.
Carisma news has also covered conference participation, with company representatives presenting at events such as the Society for Immunotherapy of Cancer (SITC), the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, and healthcare investor conferences hosted by firms like Oppenheimer, Evercore ISI, and H.C. Wainwright. These announcements often summarize new data, poster presentations, and updates on the company’s pipeline strategy.
More recent news has focused on strategic alternatives, restructuring, and listing status. Carisma has announced workforce reductions, the pausing or discontinuation of certain programs, and a revised operating plan centered on evaluating strategic options and preserving capital. Additional releases have detailed the company’s noncompliance with Nasdaq listing requirements, the suspension of trading on Nasdaq, the commencement of trading on the OTCID market tier, and the Board’s decision to voluntarily delist and deregister its common stock as part of an orderly wind down of operations.
Investors and observers following the CARM news feed can review this sequence of scientific, strategic, and regulatory announcements to understand how Carisma’s macrophage engineering platform evolved, how its collaboration with Moderna changed over time, and how the company moved from active development to asset monetization and wind down planning.
Carisma Therapeutics (Nasdaq: CARM) announced that the FDA granted Fast Track designation for CT-0525, a gene-modified cellular therapy for HER2-overexpressing solid tumors. This designation aims to expedite the development and review of therapies addressing serious conditions with unmet medical needs. The Phase 1 clinical trial is ongoing, focusing on safety, tolerability, and manufacturing feasibility. Initial data is expected by the end of 2024. The trial targets patients with advanced or metastatic solid tumors unresponsive to standard therapies.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced its participation in the Jefferies Global Healthcare Conference. Steven Kelly, President and CEO, will join a fireside chat on June 6, 2024, at 3:00 pm ET. An audio webcast will be available on the Investor Events section of the company's website and archived for a time.
Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in design, aims to evaluate the safety, tolerability, and manufacturing feasibility of CT-0525. It will include patients with advanced or metastatic HER2-positive tumors that have not responded to standard therapies. The trial's design will be featured at the ASCO 2024 Annual Meeting.
Carisma Therapeutics Inc. (Nasdaq: CARM) reported financial results for Q1 2024 and highlighted recent business updates. The company announced CT-0525 as the lead product candidate for the anti-HER2 program, presented preclinical proof of concept data in liver fibrosis, and reported Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508. Carisma plans to treat the first patient in the CT-0525 Phase 1 clinical study in Q2 2024 and expects to have initial data by year-end 2024. The company also reported a cash balance of $56.5 million, expected to fund operations into Q3 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) presented groundbreaking preclinical data at ASGCT 2024, showcasing the efficacy of engineered macrophages in reducing liver fibrosis. The therapy demonstrated significant reductions in fibrosis in liver and lung models, offering promising solutions for metabolic dysfunction-associated diseases. Carisma plans to nominate a development candidate for its liver fibrosis program in early 2025.
Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.
Carisma Therapeutics Inc. (Nasdaq: CARM) has appointed Dr. Eugene P. Kennedy as the Chief Medical Officer. Dr. Kennedy, with over 15 years of experience in clinical and industry settings, will oversee Carisma's clinical development, regulatory, and medical affairs functions. His expertise in oncology and immuno-oncology is expected to positively impact the organization and advance their clinical program and pipeline.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
